{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:58:11Z","timestamp":1781179091198,"version":"3.54.1"},"reference-count":19,"publisher":"Scientific Scholar","issue":"02","license":[{"start":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T00:00:00Z","timestamp":1645920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Asian J Cancer"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:p>Background\u2003Human Epididymis protein 4 (HE4) is expressed in ovarian cancer. Preoperative serum testing is still not widely available. This pilot study aimed to investigate the magnitude of expression of HE4 in tissue sections of serous epithelial ovarian carcinoma, its correlation with clinical outcome, and the feasibility of HE4 immunohistochemistry as a prognostic marker.<\/jats:p>\n                  <jats:p>Materials and Method\u2003In this ambispective study, immunohistochemistry (IHC) was used to evaluate tissue sections of ovarian serous epithelial carcinoma at primary cytoreductive surgery. On HE4 immunohistochemistry (IHC), the magnitude of HE4 expression was assessed categorically as high or low HE4 expression and semiquantitatively by the H-score, and correlated with clinical outcome in terms of survival status, progression-free survival, and overall survival.<\/jats:p>\n                  <jats:p>Results\u2003Of 32 cases, most (n\u2009=\u200931, 96.8%) were positive for HE4 IHC. The mean age was 49\u2009\u00b1\u20098.2 years; 29 (90.6%) patients were in FIGO stage IIIC; 25 (78.9%) had \u22651cm residual disease after surgery; 31 (96.8%) received adjuvant chemotherapy, either 3-weekly (n\u2009=\u200925, 81.2%) or dose-dense weekly (n\u2009=\u20096, 18.8%) regimen. The majority (n\u2009=\u200931, 96.8%) had a high-grade tumor, of whom 19 (59.4%) had high HE4 expression and 13(40.6%) patients had H-score in the range of 5 to 8. The mean H-score was 6.97\u2009\u00b1\u20093.61 (range 0 to 12). The overall survival of the study population at 64 months was 36.65% (95% CI: 8.59\u201366.34), with median overall survival of 59 months. A new scoring system was developed combining categorical HE4 expression and serum CA-125 levels; the combination of HE4 expression with postoperative CA-125 levels was found to be the best prognostic marker for overall survival (p\u2009=\u20090.05). A composite score of 2 identified patients with poor progression-free survival (HR 4.64, p\u2009=\u20090.039) and overall survival (HR 5.45, p\u2009=\u20090.05).<\/jats:p>\n                  <jats:p>Conclusion\u2003The new composite scoring system using HE4 IHC with postoperative serum CA-125 levels offers an extremely useful option for prognosticating patients with serous epithelial ovarian carcinoma than serum CA-125 alone. This is useful where preoperative records are not available to the treating clinician.<\/jats:p>","DOI":"10.1055\/s-0042-1742711","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T18:33:26Z","timestamp":1645986806000},"page":"125-132","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic Significance of HE4 Tissue Expression in Serous Epithelial Ovarian Carcinoma"],"prefix":"10.25259","volume":"11","author":[{"given":"Ankita","family":"Sethi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Mathur","sequence":"additional","affiliation":[{"name":"Department of Pathology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reeta","family":"Mahey","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garima","family":"Kachhawa","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neerja","family":"Bhatla","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2022,2,27]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0889-8588(03)00063-7","article-title":"Ovarian cancer screening","volume":"17","author":"N Urban","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","article-title":"Cancer statistics, 2006","volume":"56","author":"A Jemal","year":"2006","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1008240421028","article-title":"Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]","volume":"8","author":"E A Eisenhauer","year":"1997","journal-title":"Ann Oncol"},{"issue":"05","key":"ref4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3322\/canjclin.49.5.297","article-title":"Epithelial ovarian cancer: prevention, diagnosis, and treatment","volume":"49","author":"E E Partridge","year":"1999","journal-title":"CA Cancer J Clin"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0378-1119(99)00342-X","article-title":"Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas","volume":"238","author":"M Schummer","year":"1999","journal-title":"Gene"},{"issue":"13","key":"ref6","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"I Hellstr\u00f6m","year":"2003","journal-title":"Cancer Res"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","article-title":"Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas","volume":"65","author":"R Drapkin","year":"2005","journal-title":"Cancer Res"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/(SICI)1098-2264(199712)20:4<320::AID-GCC2>3.0.CO;2-3","article-title":"Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas","volume":"20","author":"G Sonoda","year":"1997","journal-title":"Genes Chromosomes Cancer"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bbrc.2012.02.008","article-title":"Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility","volume":"419","author":"R Lu","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1995-7645(13)60055-3","article-title":"Effect of WFDC 2 silencing on the proliferation, motility and invasion of human serous ovarian cancer cells in vitro","volume":"6","author":"Y-F Zhu","year":"2013","journal-title":"Asian Pac J Trop Med"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"R G Moore","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"06","key":"ref12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","article-title":"Comprehensive analysis of HE4 expression in normal and malignant human tissues","volume":"19","author":"M T Galgano","year":"2006","journal-title":"Mod Pathol"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/GCO.0b013e3282f2b124","article-title":"Cancer antigen 125 and prognosis","volume":"20","author":"E H\u00f8gdall","year":"2008","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"09","key":"ref14","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1038\/bjc.2016.330","article-title":"HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia","volume":"115","author":"A \u00d8rbo","year":"2016","journal-title":"Br J Cancer"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/modpathol.2009.35","article-title":"ALDH1 expression correlates with favorable prognosis in ovarian cancers","volume":"22","author":"B Chang","year":"2009","journal-title":"Mod Pathol"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1038\/srep05500","article-title":"HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation","volume":"4","author":"E Lokich","year":"2014","journal-title":"Sci Rep"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1080\/0284186X.2020.1827157","article-title":"HE4 in the evaluation of tumor load and prognostic stratification of high grade serous ovarian carcinoma","volume":"59","author":"L Salminen","year":"2020","journal-title":"Acta Oncol"},{"issue":"06","key":"ref18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.5372\/1905-7415.0506.103","article-title":"The expression of human epididymis protein 4 and cyclindependent kinase inhibitor p27Kip1 in human ovarian carcinoma","volume":"5","author":"M Lu","year":"2017","journal-title":"Asian Biomedicine"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13048-020-00681-0","article-title":"Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer","volume":"13","author":"S Piatek","year":"2020","journal-title":"J Ovarian Res"}],"container-title":["South Asian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1742711.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:12:31Z","timestamp":1781176351000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.sajc.org\/prognostic-significance-of-he4-tissue-expression-in-serous-epithelial-ovarian-carcinoma\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,27]]},"references-count":19,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2022,12,2]]},"published-print":{"date-parts":[[2022,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1742711","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2278-330X","2278-4306"],"issn-type":[{"value":"2278-330X","type":"print"},{"value":"2278-4306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,27]]}}}